For the estimated 700,000 people in the United States who suffer from Crohn’s disease (CD), there are multiple prescription therapies that are available for treating the associated symptoms. The…
The late-stage development pipeline for non-small-cell lung cancer (NSCLC) is one of the busiest pipelines in oncology, with approximately 25 novel therapies in Phase III development. Several of…
Cancer treatment is rapidly evolving and demand for more than modest incremental efficacy gains in highly competitive markets is growing. Given the complexity of the multiple pathways and aberrant…
How Does Cost versus Dosing Impact Prescriber Preferences and Payer Policy? The prevalence of age-related macular degeneration (AMD) is increasing with the aging population in China. Therapies…
Dyslipidemia is a risk factor for the development of cardiovascular disease and one of the most prevalent diseases in the United States. The efficacy of statins has led to their dominance in the…
Last Updated 28 September 2015 The market for Alzheimer’s disease (AD) pharmacotherapies offers enormous commercial opportunity driven by considerable unmet need and looming societal burden. The…
How Are Payer Strategies and Prescriber Preferences Shaping the Non-Insulin Treatment Algorithm? Although a high opportunity market, the therapeutic space for type 2 diabetes (T2D) is set to…
Medical device companies developing products for drug-treated populations must understand the clinical, health economic, and marketing challenges that manifest from this convergence, or risk their…
Increasing formulary competition and decreasing product differentiation have led to an aggressive pricing war in the U.S. asthma and chronic obstructive pulmonary disorder (COPD) markets. As…
Gastric and gastroesophageal junction (GEJ) adenocarcinoma is characterized by poor prognosis. Japan has the highest incidence of gastric and GEJ adenocarcinoma among the markets under study,…
Gram-negative pathogens (GNPs) are clinically important pathogens in both the hospital and outpatient settings. GNPs are often acquired in healthcare facilities, and therefore have a high incidence…
For regenerative medicine to truly deliver on its potential, one important stakeholder, medical device companies, have to come to grips with the increasing role of regenerative medicine in patient…
Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting multiple organ systems, manifesting at various levels of severity, and involving periods of flare-up and remission. The…
LaunchTrends: Entyvio Wave 3 (US) measures the impact of this novel agent on the moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD) market one year following launch. The report…
The ovarian cancer therapy market retains its potential for commercial reward for drug developers. Although the disease tends to respond well initially to chemotherapy and current drug treatment…
